Twin Tree Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Twin Tree Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-73,500	Closed	-$5.34M	–	1796
2022 Q1	$5.34M	Buy	+73,500	New	+$5.11M	0.01%	906
2016 Q1	–	Sell	-4,600	Closed	-$516K	–	1450
2015 Q4	$516K	Sell	4,600 -5,100	-53%	-$510K	0.01%	855
2015 Q3	$934K	Buy	+9,700	New	+$1.11M	0.02%	567

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Twin Tree Management's RARE Position: Q2 2022 in Review

Twin Tree Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2022, closing a stake of 23,726 shares — an estimated $1.72M sold.

Twin Tree Management first reported a position in RARE in Q3 2015 and held it in 3 quarters. The position peaked at $1.72M in Q1 2022. 223 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

Twin Tree Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Twin Tree Management sold 23,726 Ultragenyx Pharmaceutical shares in Q2 2022, an estimated $1.72M.
Twin Tree Management first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 3 quarters.
Twin Tree Management's Ultragenyx Pharmaceutical position peaked at $1.72M in Q1 2022.
223 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on Twin Tree Management's 13F filing for Q2 2022, filed 11 Aug 2022.